The Centers for Medicare & Medicaid Services today announced four concepts that states can use to promote health coverage options under Section 1332 of the Affordable Care Act: account-based subsidies; state-specific premium assistance; adjusted plan options; and risk stabilization strategies. Specifically, the agency said the concepts allow a state to direct public subsidies into defined-contribution, consumer-directed accounts to pay for health insurance premiums or other health care expenses; design a subsidy structure that meets the unique needs of its population; provide financial assistance for different types of health insurance plans; and more flexibility to implement reinsurance programs or high-risk pools. “CMS and the Department of the Treasury look forward to engaging with states on these waiver concepts, which illustrate concepts that the Administration supports and that fit within the framework outlined in section 1332 of the Affordable Care Act,” the agency said. The departments last month issued updated guidance for states seeking to waive certain ACA requirements under Section 1332 beginning in plan year 2020. 
 

Related News Articles

Headline
The Department of Homeland Security Nov. 17 published a proposed rule regarding “Public Charge Ground of Inadmissibility.” DHS proposed to…
Headline
The AHA and the Federation of American Hospitals Nov. 18 released a study conducted by Dobson | DaVanzo, underscoring the threat to patient care…
Headline
Medicaid enrollment decreased 7.6% in fiscal year 2025 and is expected to be mostly flat in FY 2026, according to KFF’s annual Medicaid Budget Survey released…
Blog
Public
The health care field has entered a period of disruption, from sweeping coverage changes to the rise of artificial intelligence (AI)-enabled tools. The…
Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…